Predictive biomarker for irinotecan and topotecan class of drug.
What is it about?
The publication describes the technology of an IHC based test that has the potential to predict the response of a class of cancer drug. The commonly used drugs in this class is topotecan and irinotecan for gastric, colon, ovary and pancreatic cancer.
Why is it important?
This test will an important tool for oncologist to identify the responder patients for this class of drug. An important test in the field of personalized medicine.
The following have contributed to this page: Ajit Bharti
In partnership with: